Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 60   

Articles published

ARNA 4.33 -0.01 (-0.23%)
price chart
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Related articles »  
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Related articles »  
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Related articles »  
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Related articles »  
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
Related articles »  
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
Related articles »  
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Related articles »  
How Much Can Vivus, Arena Pharma Charge for Diet Pills?
Lief told investors on a conference call that his company's partnership with Eisai is one of the reasons he feels confident about his drug's chances for success.
Related articles »  
University of Iowa Research Foundation increases funding efforts to promote ...
A company wants something that is as close to a sure thing as it can possibly be.� To entice potential investors, Bishop and Vanden Bush must complete further tests and proof of concept work, and the University of Iowa Research Foundation has ...